Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria

Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications

(2011) Christian Hampp et al.   ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE

The relationship between RSV bronchiolitis and recurrent wheeze: The chicken and the egg

(2011) L. Bont et al.   EARLY HUMAN DEVELOPMENT

Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis

(2010) E. Rietveld et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Scope and Impact of Early and Late Preterm Infants Admitted to the PICU with Respiratory Illness

(2010) Cameron F. Gunville et al.   JOURNAL OF PEDIATRICS

Risk Factors in Children Hospitalized With RSV Bronchiolitis Versus Non-RSV Bronchiolitis

(2010) C. G. Garcia et al.   PEDIATRICS

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life

(2010) N. Sigurs et al.   THORAX

Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention

(2009) Dan L. Stewart et al.   CURRENT MEDICAL RESEARCH AND OPINION

Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung

(2009)   MONATSSCHRIFT KINDERHEILKUNDE

The Burden of Respiratory Syncytial Virus Infection in Young Children

(2009) Caroline Breese Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria

(2008) Bernhard Resch et al.   CLINICAL THERAPEUTICS

Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants

(2008) Bernhard Resch   Expert Review of Pharmacoeconomics & Outcomes Research